| Market Cap | 120.16M | P/E | - | EPS this Y | 35.70% | Ern Qtrly Grth | - |
| Income | -227.28M | Forward P/E | -0.64 | EPS next Y | 16.40% | 50D Avg Chg | -26.00% |
| Sales | 68.62M | PEG | -0.13 | EPS past 5Y | - | 200D Avg Chg | -51.00% |
| Dividend | N/A | Price/Book | 3.20 | EPS next 5Y | 15.80% | 52W High Chg | -86.00% |
| Recommedations | 1.90 | Quick Ratio | 4.09 | Shares Outstanding | 96.23M | 52W Low Chg | 22.00% |
| Insider Own | 21.06% | ROA | -24.08% | Shares Float | 67.20M | Beta | 1.60 |
| Inst Own | 42.01% | ROE | - | Shares Shorted/Prior | 3.19M/822.45K | Price | 1.49 |
| Gross Margin | -92.65% | Profit Margin | - | Avg. Volume | 519,106 | Target Price | 10.00 |
| Oper. Margin | -186.19% | Earnings Date | Aug 6 | Volume | 339,555 | Change | -1.32% |
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
| Cantor Fitzgerald | Overweight | May 30, 24 |
| HC Wainwright & Co. | Buy | May 7, 24 |
| HC Wainwright & Co. | Buy | Apr 15, 24 |
| Guggenheim | Buy | Apr 5, 24 |
| Guggenheim | Buy | Mar 28, 24 |
| RBC Capital | Outperform | Mar 14, 24 |
| HC Wainwright & Co. | Buy | Mar 6, 24 |
| RBC Capital | Outperform | Feb 26, 24 |
| HC Wainwright & Co. | Buy | Feb 20, 24 |